Skip to main content

GIVLAARI Alnylam Australia Pty Ltd

Product name
Accepted date
Active ingredients
givosiran sodium
Proposed indication
For the treatment of acute hepatic porphyria.
Application type
A (new medicine)
Publication date

Registration process

Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.

Help us improve the Therapeutic Goods Administration site